A PHASE 1 TRIAL OF THE PARP INHIBITOR VELIPARIB IN COMBINATION WITH INTRAPERITONEAL FLOXURIDINE (FUDR) IN EPITHELIAL OVARIAN CANCER

被引：0
|
作者：
Hendrickson, A. Wahner [1 ]
Powell, M. [2 ]
Mutch, D. [2 ]
Tanner, E. [3 ]
Cliby, W. [4 ]
Swisher, E. [5 ]
Ralya, A. [6 ]
Reid, J. [7 ]
Burton, J. [1 ]
Wagner, J. [1 ]
Strand, C. [8 ]
Allred, J. [8 ]
Haluska, P. [9 ]
Erlichman, C. [1 ]
Ivy, S. P. [10 ]
Kaufmann, S. [1 ]
Karnitz, L. [11 ]
机构：
[1] Mayo Clin, Med Oncol, Rochester, MN USA
[2] Washington Univ, Gynecol Surg, St Louis, MO 63110 USA
[3] Johns Hopkins Univ, Gynecol & Obstet, Baltimore, MD USA
[4] Mayo Clin, Obstet & Gynecol, Rochester, MN USA
[5] Univ Washington, Obstet & Gynecol, Seattle, WA 98195 USA
[6] IQVIA, Clin PK PD, Overland Pk, KS USA
[7] Mayo Clin, Pharmacol, Rochester, MN USA
[8] Mayo Clin, Biomed Stat, Rochester, MN USA
[9] Merck & Co Inc, Oncol, Rahway, NJ 07065 USA
[10] NCI, NIH, Invest Drug Branch, CTEP, Bethesda, MD 20892 USA
[11] Mayo Clin, Oncol Res, Rochester, MN USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS8-0369
引用
收藏
页码：460 / 461
页数：2
相关论文
共 50 条
  • [21] A SYNERGISTIC ANTICANCER EFFECT OF COMBINATION TREATMENT WITH A CELL CYCLE CHECKPOINT KINASE 1 INHIBITOR AND PARP INHIBITOR IN BRCA WILD TYPE EPITHELIAL OVARIAN CANCER
    Kim, Y. B.
    Cho, H-Y
    Park, W. H.
    Suh, D. H.
    No, J. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A480 - A480
  • [22] PHASE-II TRIAL OF WEEKLY OR BIWEEKLY INTRAPERITONEAL MITOXANTRONE IN EPITHELIAL OVARIAN-CANCER
    MARKMAN, M
    HAKES, T
    REICHMAN, B
    LEWIS, JL
    RUBIN, S
    JONES, W
    ALMADRONES, L
    HOSKINS, W
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (06) : 978 - 982
  • [23] Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor- Resistant Homologous Recombination-Deficient Ovarian Cancer
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie
    Tanyi, Janos L.
    Latif, Nawar
    Morgan, Mark
    Torigian, Drew A.
    Rodriguez, Diego
    Smith, Simon A.
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei -Ting
    Armstrong, Deborah K.
    Gaillard, Stephanie
    Giuntoli, Robert
    Simpkins, Fiona
    CLINICAL CANCER RESEARCH, 2023, 29 (15) : 2800 - 2807
  • [24] Olaparib, PARP1 inhibitor in ovarian cancer
    Marchetti, Claudia
    Imperiale, Ludovica
    Gasparri, Maria Luisa
    Palaia, Innocenza
    Pignata, Sandro
    Boni, Terenzio
    Bellati, Filippo
    Panici, Pierluigi Benedetti
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1575 - 1584
  • [25] An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
    Xu, Jing
    Gao, Yi
    Luan, Xiaotian
    Li, Ke
    Wang, Jing
    Dai, Yilin
    Kang, Mingyi
    Lu, Chong
    Zhang, Minhua
    Lu, Chris X.
    Kang, Yu
    Xu, Congjian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (05) : 683 - 695
  • [26] Anti-tumor effects in combination with PARP inhibitor and DNMT inhibitor in ovarian cancer
    Lee, Jeong-Won
    Jeong, Soo Young
    Ryu, Ji Yoon
    Lee, Yoo-Young
    Esun, Paik
    CANCER RESEARCH, 2019, 79 (13)
  • [27] An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
    Jing Xu
    Yi Gao
    Xiaotian Luan
    Ke Li
    Jing Wang
    Yilin Dai
    Mingyi Kang
    Chong Lu
    Minhua Zhang
    Chris X. Lu
    Yu Kang
    Congjian Xu
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 683 - 695
  • [28] Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer
    Dockery, Lauren E.
    Tew, William P.
    Ding, Kai
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (03) : 509 - 513
  • [29] Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancer
    Lin, Z. P.
    Zhu, Y. L.
    Huang, P. H.
    Ratner, E. S.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 74 - 74
  • [30] A PHASE-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ETOPOSIDE FOR PRIMARY-TREATMENT OF OVARIAN EPITHELIAL CANCER
    HOWELL, SB
    KIRMANI, S
    LUCAS, WE
    ZIMM, S
    GOEL, R
    KIM, S
    HORTON, MC
    MCVEY, L
    MORRIS, J
    WEISS, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) : 137 - 145
12345